Caris Life Sciences to Present Molecular Insights Informing Treatment Strategies at the 2016 Society of Gynecologic Oncology Annual Meeting

Awarded Featured Poster Status for Key Findings Using Caris Molecular Intelligence

News provided by

Mar 15, 2016, 07:00 ET

IRVING, Texas, March 15, 2016 /PRNewswire/ -- Caris Life Sciences^®, a leading biotechnology company focused on fulfilling the promise of precision medicine, announced today that the company will present seven poster presentations at the 2016 Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancers from March 19-22, 2016 in San Diego, Calif. One of the seven studies, which identified biomarkers implicating drug resistance and alternate treatment options in uterine leiomyosarcomas, was awarded featured poster status.

Each of the studies being presented were conducted in collaboration with leading academic and clinical institutions across the nation, including New York-Presbyterian, Columbia University Medical Center, Weill Cornell Medical College and Fox Chase Cancer Center. The collective set of studies utilized Caris Molecular Intelligence^® (CMI), the company's patented and proprietary offering to help physicians make informed therapy decisions, which facilitated biomarker identification and molecular characterization of rare and aggressive gynecologic cancers across different subtypes. The use of CMI enabled investigators to identify the molecular heterogeneity of gynecologic cancers and inform physicians on therapeutic options, including therapies with potential benefit to consider and, just as important, therapies to avoid due to potential lack of benefit.

Following is a schedule of Caris Life Sciences' poster presentations:

Title:	Uterine leiomyosarcomas exhibit distinct drug resistance molecular profiles compared to extrauterine leiomyosarcomas: A comprehensive analysis of 1,023 leiomyosarcomas
Date and Time:	Sunday March 20, 2016 and Monday, March 21, 2016 from 10:25–10:45 a.m. PT
Abstract #:	124
Location:	Hall B1
Session:	Featured Poster Session I
Authors:	Sudeshna Chatterjee, Joanne Xiu, Sandeep Reddy, Nathaniel Jones, Alexandre Buckley de Meritens, Ana Tergas, William Burke, Jason Wright, June Hou
Collaborators:	NewYork-Presbyterian Hospital, Columbia University Medical Center, Weill Cornell Medical College, Columbia University College of Physicians and Surgeons

Title:	Vulvar and vaginal melanoma: A distinct subclass of melanoma based on a comprehensive molecular analysis of 51 cases
Date and Time:	Sunday March 20, 2016 and Monday, March 21, 2016 from 8:45–9:05 a.m. PT
Abstract #:	257
Location:	Hall B1
Session:	Poster Session 1
Authors:	Caitlin Baptiste, William Burke, Rebecca Feldman, Jason Wright, Ana Tergas, June Hou
Collaborators:	New York-Presbyterian Hospital, Columbia University Medical Center, Columbia University College of Physicians and Surgeons

Title:	Identification of molecular targets in vulvar cancers
Date and Time:	Sunday March 20, 2016 and Monday, March 21, 2016 from 12:25–12:45 p.m. PT
Abstract #:	271
Location:	Hall B1
Session:	Poster Session 1
Authors:	Premal Thaker, Marguerite Palisoul, Sandeep Reddy, Rebecca Feldman
Collaborator:	Washington University School of Medicine in St. Louis

Title:	Multiplatform tumor-profiling of 43 malignant Sertoli-Leydig cell tumors of the ovary reveals therapeutic opportunities
Date and Time:	Sunday March 20, 2016 and Monday, March 21, 2016 from 2:45–3:05 p.m. PT
Abstract #:	267
Location:	Hall B1
Session:	Poster Session 1
Authors:	Joanne Xiu, Sandeep Reddy, Christina Chu
Collaborator:	Fox Chase Cancer Center

Title:	Unique molecular signatures between high-grade and low-grade endometrial stromal sarcoma: An analysis of 96 cases
Date and Time:	Sunday March 20, 2016 and Monday, March 21, 2016 from 6:45–7:05 p.m. PT
Abstract #:	379
Location:	Hall B1
Session:	Poster Session 1
Authors:	Nathaniel Jones, Joanne Xiu, Sandeep Reddy, Sudeshna Chatterjee, Alexandre Buckley de Meritens, Ana Tergas, William Burke, Jason Wright, June Hou
Collaborators:	New York-Presbyterian, Columbia University Medical Center, Weill Cornell Medical College, Columbia University College of Physicians and Surgeons

Title:	Molecular profiling of triple-negative endometrial cancers and triple-negative breast cancers reveals unique expression profiles
Date and Time:	Sunday, March 20, 2016 and Monday, March 21, 2016 from 7:05–7:25 p.m. PT
Abstract #:	166
Location:	Hall B1
Session:	Poster Session 1
Authors:	Nathaniel Jones, Joanne Xiu, Sandeep Reddy, Sudeshna Chatterjee, Alexandre Buckley de Meritens, Ana Tergas, William Burke, Jason Wright, June Hou
Collaborators:	New York-Presbyterian, Columbia University Medical Center, Weill Cornell Medical College, Columbia University College of Physicians and Surgeons

Title:	Molecular profiling reveals distinct molecular landscape in 545 cases of triple-negative endometrial cancer
Date and Time:	Sunday March 20, 2016 and Monday, March 21, 2016 from 9:45–10:05 p.m. PT
Abstract #:	167
Location:	Hall B1
Session:	Poster Session 1
Authors:	Nathaniel Jones, Joanne Xiu, Sandeep Reddy, Alexandre Buckley de Meritens, Sudeshna Chatterjee, Ana Tergas, William Burke, Jason Wright, June Hou
Collaborators:	New York-Presbyterian, Columbia University Medical Center, Weill Cornell Medical College, Columbia University College of Physicians and Surgeons

About Caris Life Sciences^®
Founded by David D. Halbert in 2008, Caris Life Sciences^® is a leading biotechnology company focused on fulfilling the promise of precision medicine through quality and innovation. Caris Molecular Intelligence^®, the company's patented offering to help physicians make more informed therapy decisions, with more than 85,000 patients profiled, provides oncologists with the most clinically actionable treatment options available to personalize cancer care today. Using a variety of advanced profiling technologies to assess relevant biological changes in each patient's tumor, Caris Molecular Intelligence connects biomarker data generated from a tumor with biomarker-drug associations supported by evidence in the relevant clinical literature through a proprietary bioinformatics rules engine. Since 2009, Caris Life Sciences has tracked clinical and outcome data for certain patients undergoing tumor profiling, and has observed that patients treated with drugs consistent with their tumor profile show a significant increase in overall survival. The company is also developing its ADAPT Biotargeting System^™, a revolutionary and unbiased profiling platform with applications across therapy development, drug delivery, advanced diagnostics and disease monitoring. Currently being developed for cancer and other complex diseases, the ADAPT Biotargeting System is able to simultaneously measure millions of molecular interactions within complex biological systems in their natural state(s). Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Australia and other international markets. To learn more, please visit www.CarisLifeSciences.com.

SOURCE Caris Life Sciences